Sold as Polycillin-Prb, Principen W/ Probenecid. Every FDA application for this active ingredient: 2 branded and 3 generic.
As of Nov 15, 2026, FDA lists 5 applications for Ampicillin/Ampicillin Trihydrate; Probenecid (sold as Polycillin-Prb, Principen W/ Probenecid), with 0 new uses approved and 0 published complete response letters.
| Oct 10, 1973 | ProbampacinANDA 61741 | Cosette Pharms Nc | 1 | Discontinued |
| Dec 16, 1974 | Polycillin-PrbANDA 61898 | Apothecon | 0 | Discontinued |
| — | Principen W/ ProbenecidANDA 62150 | Apothecon | 0 | Discontinued |
| — | Polycillin-PrbNDA 50457 | Bristol | 0 | Discontinued |
| — | Principen W/ ProbenecidNDA 50488 | Apothecon | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Apothecon